MedTrace Logo

Efficacy and Safety of Tabetri on Osteoarthritis

NCT03757611 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2018-11-30

No results posted yet for this study

Summary

This study is a 12-week, multicenter, randomized, double-blind, placebo-controlled clinical trial in order to evaluate the efficacy and safety of tabetri on osteoarthritis.

Conditions

Interventions

DIETARY_SUPPLEMENT

Tabetri capsule

1,000 mg/capsule (Taheebo extract 600 mg/day)

DIETARY_SUPPLEMENT

Placebo capsule

1,000 mg/capsule

Sponsors & Collaborators

  • Nutribiotech Co., Ltd.

    collaborator INDUSTRY

  • Neonutra

    collaborator INDUSTRY

  • Jaseng Medical Foundation

    lead OTHER

Principal Investigators

  • In-Hyuk Ha, KMD, MPH · Jaseng Medical Foundation

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-31
Primary Completion
2018-03-13
Completion
2018-06-15

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03757611 on ClinicalTrials.gov